Key result
Premature cardiovascular disease mortality resulted in overall median YPLL and SEYLL rates of 594.2 and 1357.0 per 100,000 population, respectively, remaining a major burden particularly in middle-income countries and among men.
Why the study?
To identify studies on premature cardiovascular disease mortality and synthesize their findings on years of life lost based on regional area, main CVD types, sex, and study time.
Systematic Review (n=40)
Premature CVD mortality continues to be a major burden for middle-income countries and men, with YLL rates showing no decline over the past three decades.
Answers are grounded in this paper and cite their sources.
Premature CVD mortality remains a major burden in middle-income countries and men; confirms stalled progress over three decades and supports targeted prevention research.
INTRODUCTION: Premature mortality refers to deaths that occur before the expected age of death in a given population. Years of life lost (YLL) is a standard parameter that is frequently used to quantify some component of an "avoidable" mortality burden. OBJECTIVE: To identify the studies on premature cardiovascular disease (CVD) mortality and synthesise their findings on YLL based on the regional area, main CVD types, sex, and study time. METHOD: We conducted a systematic review of published CVD mortality studies that reported YLL as an indicator for premature mortality measurement. A literature search for eligible studies was conducted in five electronic databases: PubMed, Scopus, Web of Science (WoS), and the Cochrane Central Register of Controlled Trials (CENTRAL). The Newcastle-Ottawa Scale was used to assess the quality of the included studies. The synthesis of YLL was grouped into years of potential life lost (YPLL) and standard expected years of life lost (SEYLL) using descriptive analysis. These subgroups were further divided into WHO (World Health Organization) regions, study time, CVD type, and sex to reduce the effect of heterogeneity between studies. RESULTS: Forty studies met the inclusion criteria for this review. Of these, 17 studies reported premature CVD mortality using YPLL, and the remaining 23 studies calculated SEYLL. The selected studies represent all WHO regions except for the Eastern Mediterranean. The overall median YPLL and SEYLL rates per 100,000 population were 594.2 and 1357.0, respectively. The YPLL rate and SEYLL rate demonstrated low levels in high-income countries, including Switzerland, Belgium, Spain, Slovenia, the USA, and South Korea, and a high rate in middle-income countries (including Brazil, India, South Africa, and Serbia). Over the past three decades (1990-2022), there has been a slight increase in the YPLL rate and the SEYLL rate for overall CVD and ischemic heart disease but a slight decrease in the SEYLL rate for cerebrovascular disease. The SEYLL rate for overall CVD demonstrated a notable increase in the Western Pacific region, while the European region has experienced a decline and the American region has nearly reached a plateau. In regard to sex, the male showed a higher median YPLL rate and median SEYLL rate than the female, where the rate in males substantially increased after three decades. CONCLUSION: Estimates from both the YPLL and SEYLL indicators indicate that premature CVD mortality continues to be a major burden for middle-income countries. The pattern of the YLL rate does not appear to have lessened over the past three decades, particularly for men. It is vitally necessary to develop and execute strategies and activities to lessen this mortality gap. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42021288415.
No takes yet. Share an insight, caveat, or question.
Hasani et al. (2023) conducted a systematic review in Premature mortality from cardiovascular diseases (n=40). Premature cardiovascular disease mortality was evaluated on Years of potential life lost (YPLL) and standard expected years of life lost (SEYLL) rates per 100,000 population. Premature cardiovascular disease mortality resulted in overall median YPLL and SEYLL rates of 594.2 and 1357.0 per 100,000 population, respectively, remaining a major burden particularly in middle-income countries and among men.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: